Remicade's challenging dosing reduces its impact as an ideal ulcerative colitis drug

DURHAM, N.C. - Sept. 29, 2022 - PRLog -- Despite its strong efficacy, Remicade is facing increased competition from newer drugs and the prospect of pipeline drugs set to launch in the coming years. New data published by Vivisum Partners, LLC, a North Carolina market research firm, found that 44% of gastroenterologists identify Remicade's dosing as a key weakness that has opened the door for Entyvio to surpass it as the ideal ulcerative colitis treatment.

The two-decade old biologic gained recognition as the first advanced therapy for ulcerative colitis. Though Remicade's efficacy is not in question, gastroenterologists have more options to offer ulcerative colitis patients treatments with easier dosing schedules. With Humira offering a subcutaneous injectable and oral therapies, such as Zeposia, now available, patients and doctors view Remicade's traditional infusion therapy as inconvenient.

Vivisum analyzed gastroenterologists' perceptions of branded ulcerative colitis medications. The analysis contained in Ulcerative Colitis Rational Brand Perceptions shows that gastroenterologists rank Remicade poorly in three key clinical attributes: dosing, safety and tolerability. For all three attributes, surveyed healthcare providers (HCPs) include Remicade among the bottom two available treatments. Comparatively, Entyvio ranks among the two best treatments for safety and tolerability, as well as efficacy and manufacturer support.

The findings in Vivisum's research offers a quantitative assessment of gastroenterologists' perceptions of ulcerative colitis brands' clinical benefits. The data identify which ulcerative colitis brands HCPs perceive as the most ideal treatment. Additionally, the analysis includes a proprietary matrix of net perception scores that compares gastroenterologists' perceptions of each brand's clinical attributes. These perceptions are then mapped against brands that HCPs described as the least or most ideal ulcerative colitis drug.

The market research contained in Ulcerative Colitis Rational Brand Perceptions, found at http://vivisumpartners.com/reports/ulcerative-colitis-rat..., supports strategy development for both existing and developing ulcerative colitis brands. The report features include:

• An analytical view of the clinical brand perception landscape
• 'Net perception scores' for each branded ulcerative colitis treatment
• Gastroenterologists' rankings of most and least ideal ulcerative colitis drugs
• HCPs' rankings of each UC treatment's six clinical attributes, including efficacy, safety, dosing, tolerability, access and support
• Eight individual brand profiles covering each branded UC treatment's strengths and weaknesses
• Analysis and importance ratings for clinical attributes and their impact on the ulcerative colitis Rx decision-making process

ABOUT VIVISUM PARTNERS, LLC
Vivisum Partners, LLC is a market research agency providing strategic consulting around marketing and brand building. Vivisum provides facilitated discovery using market research methodologies and critical thinking processes. The actionable market research insights that Vivisum provides enable clients to shape their commercial strategies.